These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 9363046)

  • 41. Are placebo controls necessary to test new antidepressants and anxiolytics?
    Khan A; Khan S; Brown WA
    Int J Neuropsychopharmacol; 2002 Sep; 5(3):193-7. PubMed ID: 12366872
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Information from your family doctor. Generalized anxiety disorder.
    Am Fam Physician; 2009 May; 79(9):785-s1. PubMed ID: 20175260
    [No Abstract]   [Full Text] [Related]  

  • 43. Historical control monotherapy design in the treatment of epilepsy.
    French JA; Wang S; Warnock B; Temkin N
    Epilepsia; 2010 Oct; 51(10):1936-43. PubMed ID: 20561024
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adverse events in placebo-treated patients with generalized anxiety disorder.
    Sramek JJ; Frackiewicz EJ; Piercy MA; Kurtz NM; Murphy MF; Carta A; Cutler NR
    Depress Anxiety; 1997; 5(3):142-3. PubMed ID: 9323457
    [No Abstract]   [Full Text] [Related]  

  • 45. Use of multiple endpoints and approval paths depicts a decade of FDA oncology drug approvals.
    Shea MB; Roberts SA; Walrath JC; Allen JD; Sigal EV
    Clin Cancer Res; 2013 Jul; 19(14):3722-31. PubMed ID: 23665737
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Measurement of anxiety in outpatient trials: detection of bias in patient and doctor ratings.
    Fisher S
    Psychopharmacol Bull; 1976 Apr; 12(2):17-8. PubMed ID: 3818
    [No Abstract]   [Full Text] [Related]  

  • 47. Placebos, drug effects, and study design: a clinician's guide.
    Quitkin FM
    Am J Psychiatry; 1999 Jun; 156(6):829-36. PubMed ID: 10360119
    [TBL] [Abstract][Full Text] [Related]  

  • 48. On assessing potential efficacy for vortioxetine in generalized anxiety disorder.
    Baldwin DS; Nutt DJ
    Eur Neuropsychopharmacol; 2012 Dec; 22(12):841-3. PubMed ID: 22906521
    [No Abstract]   [Full Text] [Related]  

  • 49. [A new scale of quantitative and qualitative evaluation of anxiety: the Ferrerri Anxiety Rating Diagram (FARD)].
    Ferreri M; Von Frenckell R; Mirabel V; Tawil S; Alby JM
    Encephale; 1988; 14(5):385-93. PubMed ID: 3215140
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recent clinical trials of hydroxyzine in generalized anxiety disorder.
    Ferreri M; Hantouche EG
    Acta Psychiatr Scand Suppl; 1998; 393():102-8. PubMed ID: 9777055
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Bromazepam. Clinical trial in child-adolescent psychiatry].
    Jarrige A; Moron P
    Neuropsychiatr Enfance Adolesc; 1984 Sep; 32(9):465-70. PubMed ID: 6150452
    [No Abstract]   [Full Text] [Related]  

  • 52. Placebo response in anxiety disorders.
    Piercy MA; Sramek JJ; Kurtz NM; Cutler NR
    Ann Pharmacother; 1996 Sep; 30(9):1013-9. PubMed ID: 8876864
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Indirect comparisons in the comparative efficacy and non-inferiority settings.
    Snapinn S; Jiang Q
    Pharm Stat; 2011; 10(5):420-6. PubMed ID: 21956948
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Galvanic skin responses (GSR) and plethysmographic changes induced by chlorimipramine, imipramine and placebo.
    Lapierre YD
    Curr Ther Res Clin Exp; 1974 May; 16(5):461-9. PubMed ID: 4209521
    [No Abstract]   [Full Text] [Related]  

  • 55. Critique of the Guidelines for Clinical Evaluation of Antianxiety Drugs (HEW-FDA-77-3043).
    Cohn JB; Gottschalk LA
    Methods Find Exp Clin Pharmacol; 1979 Dec; 1(5):313-5. PubMed ID: 45206
    [No Abstract]   [Full Text] [Related]  

  • 56. Psychiatric diagnosis and clinical trial completion rates: analysis of the FDA SBA reports.
    Khan A; Schwartz K; Redding N; Kolts RL; Brown WA
    Neuropsychopharmacology; 2007 Nov; 32(11):2422-30. PubMed ID: 17314915
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Personality of panic disorder alcohol abusers.
    Reich J; Chaudry D
    J Nerv Ment Dis; 1987 Apr; 175(4):224-8. PubMed ID: 2881975
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The placebo control in clinical trials (a view from the FDA).
    Leber P
    Psychopharmacol Bull; 1986; 22(1):30-2. PubMed ID: 3726077
    [No Abstract]   [Full Text] [Related]  

  • 59. The use of one-sided tests in drug trials: an FDA advisory committee member's perspective.
    Fisher LD
    J Biopharm Stat; 1991; 1(1):151-6. PubMed ID: 1844686
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Feasibility of evaluating psychopharmaceutical agents in cooperative studies in private practice.
    Free SM; Rudnick A
    Dis Nerv Syst; 1970 Nov; 31(11):763-6. PubMed ID: 4923152
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.